GT Biopharma, Inc. (GTBP) stock forecast & analysis
7.16
NasdaqCM · USD
Down: -0.33, -4.4%
7.16Unchanged: +0.00, +0.0%
1 analysis
- Open
- 7.52
- Previous close
- 7.49
- Day range
- 7.11 – 7.52
- 52-week range
- 4.91 – 34.25
- Volume (shares)
- 37.46K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.80M
- P/E ratio
- 0.05
- Dividend yield
- Not available
- Beta
- 0.91
- Market cap
- 12.92M
Market Scanner’s AI analysis of GT Biopharma, Inc. (GTBP), updated September 2026: GT Biopharma's TriKE platform presentation and strong technical indicators contrasted with consistent operating losses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of GT Biopharma, Inc. (GTBP) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
GT Biopharma's TriKE platform presentation and strong technical indicators contrasted with consistent operating losses.
Recent analyses for GT Biopharma (GTBP) covered its upcoming presentation of the TriKE® platform for cancer treatment and its second-quarter 2026 financial results. The market analysis highlighted exceptionally strong bullish technical indicators, including significant outperformance against moving averages and high RSI and MFI readings. However, the fundamental analysis indicated a history of consistent negative operating and net income on both annual and quarterly bases.
GTBP news & sentiment
News coverage noted the upcoming presentation of GT Biopharma's TriKE® platform and its recent financial results. Social media discussion was not covered in the provided notes.
GTBP technical picture
GT Biopharma's price action demonstrated a strong uptrend, significantly outperforming its moving averages. Momentum indicators like the RSI and MFI showed extreme overbought conditions and strong buying pressure, respectively, while the MACD suggested continued upward momentum.
Fundamentals
GT Biopharma has consistently reported negative operating and net income annually from 2021 through 2025, with significant quarterly losses also noted. Total liabilities have fluctuated, showing a notable increase in 2024.
Factors discussed — upside
- Strong bullish technical trend with price significantly outperforming moving averages
- High 7-day, 30-day, and 91-day price changes indicating rapid appreciation
- RSI and MFI readings suggesting strong buying pressure
- Positive MACD indicating continued upward momentum
- Scheduled presentation of TriKE® platform for cancer treatment
Factors discussed — risks
- Consistently negative operating income and net income on an annual basis from 2021-2025
- Significant net losses reported in multiple recent quarters
- RSI at 99.16 indicating extreme overbought conditions
- Current price trading above the upper Bollinger Band
- Technical indicators
- Financial performance
- Biotechnology platform presentation
- Market sentiment
Summary updated .
GTBP technical indicators
Common technical indicators for GTBP, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.54 | Price above |
| 10-day exponential moving average | 6.44 | Price above |
| Relative strength index (14-day) | 66.23 | Neutral |
| MACD line (12/26/9) | 2.1306 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -4.48 – 11.20 | Price inside the bands |
Analyses
Recent GTBP.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for GT Biopharma, Inc.?
- The bull case for GT Biopharma centers on strong technical indicators, including significant price outperformance against moving averages and high readings for RSI and MFI, suggesting robust buying pressure and upward momentum. The company is also scheduled to present its TriKE® platform for cancer treatment.
- What are the risks for GT Biopharma, Inc.?
- Risks for GT Biopharma include a history of consistent operating and net losses on both annual and quarterly bases, with recent quarters showing significant losses. Additionally, the stock's RSI is at extremely overbought levels, and the current price is trading above the upper Bollinger Band, which could indicate potential volatility.
- Is GT Biopharma, Inc. bullish or bearish?
- Recent AI analyses of GT Biopharma, Inc. examined factors on both sides. Discussed upside: The bull case for GT Biopharma centers on strong technical indicators, including significant price outperformance against moving averages and high readings for RSI and MFI, suggesting robust buying pressure and upward momentum. The company is also scheduled to present its TriKE® platform for cancer treatment. Discussed risks: Risks for GT Biopharma include a history of consistent operating and net losses on both annual and quarterly bases, with recent quarters showing significant losses. Additionally, the stock's RSI is at extremely overbought levels, and the current price is trading above the upper Bollinger Band, which could indicate potential volatility. These are descriptive observations, not a recommendation.
- What is the latest sentiment on GT Biopharma, Inc.?
- News coverage noted the upcoming presentation of GT Biopharma's TriKE® platform and its recent financial results. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse GT Biopharma, Inc.?
- Every analysis of GT Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh GTBP.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every GTBP.US report already in the library